RAPPRapport Therapeutics, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Oversold (RSI 22). Price is −12% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit. Up 0.6% since the previous count, unchanged over three months.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RAPP is trading
Rapport Therapeutics, Inc. is +16% over the past year while the S&P 500 is +18%: 1.9 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −12%
vs 200-day average · a clear downtrend
- RSI (14)
- 22
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 42%
Below its 52-week high
Details›
- Last close2026-10-09
- $30.68
- 1 monthS&P 500 +2.7%
- −29%
- 1 yearS&P 500 +18%
- +16%
- vs 50-day average$42.27
- −27%
- 52-week high
- $52.44
- 52-week low
- $24.37
- Annualised volatility
- 120%
| Year | Return |
|---|---|
| 2026 (year to date) | +1.1% |
| 2025 | +71% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −9.9% |
| Feb | 2 | 1 of 2 | −15% |
| Mar | 2 | 1 of 2 | +3.9% |
| Apr | 2 | 2 of 2 | +10% |
| May | 2 | 1 of 2 | −4.3% |
| Jun | 2 | 1 of 2 | +18% |
| Jul | 3 | 2 of 3 | +11% |
| Aug | 3 | 2 of 3 | +12% |
| Sep | 3 | 1 of 3 | +10% |
| Oct | 3 | 1 of 3 | +2.9% |
| Nov | 2 | 1 of 2 | −2.1% |
| Dec | 2 | 1 of 2 | −10% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry